Organisation paid for research Program year 2025 Source: CMS Open Payments

USF Pharmacy Plus

Neither a doctor nor a teaching hospital

Research payments

$70,468

91 payments

Through program year 2025, USF Pharmacy Plus is reported as receiving $70,468 in research payments, across 91 payments.

By program year

1 row

Year	Kind	Amount	Payments
2025	Research	$70,468	91

Breakdown

Who paid Research payments · program year 2025

Boehringer Ingelheim International GmbH $57,073 87 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $13,354 2 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $41 2 payments

Studies the money was for Research payments · program year 2025

EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) $47,085 56 payments
A multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy $9,518 27 payments
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% $7,188 7 payments
BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) ????40% $6,677 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.